A Polyvalent RNA Vaccine Reduces the Immune Imprinting Phenotype in Mice and Induces Neutralizing Antibodies Against Omicron SARS-CoV-2

Immune imprinting is now evident in COVID-19 vaccinated people. This phenomenon may impair the development of effective neutralizing antibodies against variants of concern (VoCs), mainly Omicron and its subvariants. Consequently, the boost doses with bivalent vaccines have not shown a significant gain of function regarding the neutralization of Omicron. The approach to design COVID-19 vaccines must be revised to improve the effectiveness against VoCs. Here, we took advantage of the self-amplifying characteristic of RepRNA and developed a polyvalent formulation composed of mRNA from five VoCs. LION/RepRNA Polyvalent induced neutralizing antibodies in mice previously immunized with LION/RepRNA D614G and reduced the imprinted phenotype associated with low neutralization capacity of Omicron B.1.1.529 pseudoviruses. The polyvalent vaccine can be a strategy to handle the low neutralization of Omicron VoC, despite booster doses with either monovalent or bivalent vaccines.

References

Zhou Z, Barrett J, He X . Immune Imprinting and Implications for COVID-19. Vaccines (Basel). 2023; 11(4). PMC: 10142218. DOI: 10.3390/vaccines11040875. View

Collier A, Miller J, Hachmann N, McMahan K, Liu J, A Bondzie E . Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters. N Engl J Med. 2023; 388(6):565-567. PMC: 9847505. DOI: 10.1056/NEJMc2213948. View

Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M . A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020; 369(6504):650-655. PMC: 7319273. DOI: 10.1126/science.abc6952. View

Wrammert J, Koutsonanos D, Li G, Edupuganti S, Sui J, Morrissey M . Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011; 208(1):181-93. PMC: 3023136. DOI: 10.1084/jem.20101352. View

Erasmus J, Khandhar A, OConnor M, Walls A, Hemann E, Murapa P . An -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci Transl Med. 2020; 12(555). PMC: 7402629. DOI: 10.1126/scitranslmed.abc9396. View

Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L . Antibody Response to Omicron BA.4-BA.5 Bivalent Booster. N Engl J Med. 2023; 388(6):567-569. PMC: 9847504. DOI: 10.1056/NEJMc2213907. View

Tseng H, Ackerson B, Sy L, Tubert J, Luo Y, Qiu S . mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States. Nat Commun. 2023; 14(1):5851. PMC: 10511551. DOI: 10.1038/s41467-023-41537-7. View

Weinreich D, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R . REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2020; 384(3):238-251. PMC: 7781102. DOI: 10.1056/NEJMoa2035002. View

Voss W, Hou Y, Johnson N, Delidakis G, Kim J, Javanmardi K . Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science. 2021; 372(6546):1108-1112. PMC: 8224265. DOI: 10.1126/science.abg5268. View

10.

Hawman D, Meade-White K, Clancy C, Archer J, Hinkley T, Leventhal S . Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine. EBioMedicine. 2022; 83:104196. PMC: 9349033. DOI: 10.1016/j.ebiom.2022.104196. View

11.

Wheatley A, Fox A, Tan H, Juno J, Davenport M, Subbarao K . Immune imprinting and SARS-CoV-2 vaccine design. Trends Immunol. 2021; 42(11):956-959. PMC: 8440232. DOI: 10.1016/j.it.2021.09.001. View

12.

OConnor M, Hawman D, Meade-White K, Leventhal S, Song W, Randall S . A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned. PLoS Pathog. 2023; 19(4):e1011298. PMC: 10150980. DOI: 10.1371/journal.ppat.1011298. View

13.

Garcia-Beltran W, Lam E, St Denis K, Nitido A, Garcia Z, Hauser B . Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184(9):2372-2383.e9. PMC: 7953441. DOI: 10.1016/j.cell.2021.03.013. View

14.

Davis-Gardner M, Lai L, Wali B, Samaha H, Solis D, Lee M . Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N Engl J Med. 2022; 388(2):183-185. PMC: 9812288. DOI: 10.1056/NEJMc2214293. View

15.

Belongia E, Simpson M, King J, Sundaram M, Kelley N, Osterholm M . Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016; 16(8):942-51. DOI: 10.1016/S1473-3099(16)00129-8. View

16.

Khandhar A, Landon C, Archer J, Krieger K, Warner N, Randall S . Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model. Mol Ther. 2023; 31(4):1046-1058. PMC: 10124083. DOI: 10.1016/j.ymthe.2023.02.022. View

17.

OConnor M, Erasmus J, Randall S, Archer J, Lewis T, Brown B . A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques. Front Immunol. 2022; 12:800723. PMC: 8724308. DOI: 10.3389/fimmu.2021.800723. View

18.

DAVENPORT F, HENNESSY A . Predetermination by infection and by vaccination of antibody response to influenza virus vaccines. J Exp Med. 1957; 106(6):835-50. PMC: 2136834. DOI: 10.1084/jem.106.6.835. View

19.

Suryadevara N, Shrihari S, Gilchuk P, VanBlargan L, Binshtein E, Zost S . Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell. 2021; 184(9):2316-2331.e15. PMC: 7962591. DOI: 10.1016/j.cell.2021.03.029. View

20.

Watson O, Barnsley G, Toor J, Hogan A, Winskill P, Ghani A . Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022; 22(9):1293-1302. PMC: 9225255. DOI: 10.1016/S1473-3099(22)00320-6. View